John Hester Email & Phone Number

John is a senior sell side analyst at Bell Potter Securities in Sydney . He specialise in small and mid cap healthcare stocks, however, has also followed a wide variety of stocks over 10 years in the securities industry. These range from small biotechs to very large multinationals.. His deep know knowledge of complex stocks including Mayne Pharma, Medibank Private, Sirtex Medical and Viralytics have earned wide recognition from clients during course of 2015 and 2016. In addition to the fundamentals around capital structure and balance sheet strength, he looks for one or more of the following characteristics in a stock:Normally the CEO has had an integral part in establishing the company or providing outstanding vision. Scott Richards at Mayne Pharma and George Saviddes (former CEO of MPL) are good examples. "I take a great deal of confidence from a CEO who has grown with the company and is clever enough to surround himself with an experienced team".Secondly, if it is a technology or biotech stock, the science has to stack up. "I generally steer clear of stocks where there is an absence of solid evidence from clinical trial data. This rules out a lot of start ups and early stage companies which are not investment grade".Finally, understanding the regulatory environment is crucial. "This is why the US market is so appealing for Australian companies". There is real reward for execution as compared Europe or the Australian market for most services.John's experience in the healthcare sector is drawn from many years experience at Primary Healthcare where he gained first hand experience in the operation of general practice, medical imaging and pathology from one of Australia's leading healthcare organisations. His network of contacts includes executives at the highest levels within numerous companies, fund managers, commercial banks and investment bankers.

Listed skills include Financial Modeling, Financial Analysis, Dcf Valuation, Valuation, and 5 others.